COMBO. Actualización 2004. Criterios y pautas de terapia combinada en la diabetes tipo 2

Nadal, Josep Franch; Goday Arno, Alberto; Mata Cases, Manuel.
Av. diabetol ; 20(2): 77-112, abr. 2004. ilus, tab
Artículo en Es | IBECS (España) | ID: ibc-32676

Documentos relacionados

  1. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis.
  2. Diabetes Technology in People with Type 2 Diabetes: Novel Indications.
  3. Diverse Strategies for Modulating Insulin Resistance: Causal or Consequential Inference on Metabolic Parameters in Treatment-Naïve Subjects with Type 2 Diabetes.
  4. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
  5. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
  6. Endocrinological evaluation of dawn phenomenon in patients with diabetes and comparison of insulin glargine U-100 biosimilar (Insulin Glargine BS Injection "Lilly") and glargine U-300 (Lantus XR): a randomized controlled study.
  7. The effect of Ramadan fasting on serum osmolality in diabetic patients.
  8. LC-MS Metabolite Profiling and the Hypoglycemic Activity of <i>Morus alba</i> L. Extracts.
  9. Effects of acarbose and siglitine on blood glucose fluctuation and islet ß-cell function in patients with type 2 diabetes mellitus.
  10. In-Silico Trials for Glucose Control in Hospitalized Patients with Type 2 Diabetes.